ArticleFrontiers in public health2025
Effect of the national reimbursement drug list negotiation policy on utilization of negotiated anticancer drugs in Chinese public hospital: a quasi-natural experiment.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- International approval of Chinese pharmaceuticals: a USA-anchored analysis with comparative insights from Europe and other markets.EClinicalMedicine · 2026Article
- Regional health inequalities of anticancer drug accessibility under the National Drug Price Negotiation in China: a decomposition analysis.BMC public health · 2026Article
- Generic vs. brand-name pramipexole: effectiveness, safety, and cost comparison in a multicenter retrospective cohort study.Frontiers in aging neuroscience · 2026Article
- Cost-effectiveness analysis of combined immunotherapy regimens for non-squamous non-small lung cancer after tyrosine kinase inhibitors resistance.Frontiers in public health · 2026Article
- Cost-effectiveness of targeted therapy versus chemotherapy for patients with advanced or metastatic gastric cancer in China.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High prices have limited access to targeted anticancer drugs in China. In 2017, 18 such drugs were added to the National Reimbursement Drug List (NRDL) through national price negotiation. Method: Monthly hospital procurement data (2015-2019) from 887 public hospitals across 30 provinces were analyzed. Drug utilization was measured by expenditures and defined daily doses (DDDs). A difference-in-differences (DID) model and interrupted time series (ITS) analysis were employed to estimate policy effects. Results: Following policy implementation, total DDDs of negotiated drugs rose 4.03-fold and expenditures 3.07-fold, both exceeding cancer incidence growth. DID analysis confirmed significant increases for Western medicines (+479,100 DDDs; Conclusion: The NRDL negotiation substantially improved access to targeted anticancer therapies in public hospitals while containing cost growth. These findings highlight the effectiveness of centralized price negotiation in expanding coverage and equity of high-cost cancer treatments in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.